Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study

Armando Santoro; Lorenza Rimassa; Ivan Borbath; Bruno Daniele; Stefania Salvagni; Jean Luc Van Laethem; Hans Van Vlierberghe; Jörg Trojan; Frank T Kolligs; Alan Weiss; Steven Miles; Antonio Gasbarrini; Monica Lencioni; Luca Cicalese; Morris Sherman; Cesare Gridelli; Peter Buggisch; Guido Gerken; Roland M Schmid; Corrado Boni; Nicola Personeni; Ziad Hassoun; Giovanni Abbadessa; Brian Schwartz; Reinhard Von Roemeling; Maria E Lamar; Yinpu Chen; Camillo Porta

doi:10.1016/S1470-2045(12)70490-4

Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study

Armando Santoro
, Lorenza Rimassa
, Ivan Borbath
, Bruno Daniele
, Stefania Salvagni
, Jean Luc Van Laethem
, Hans Van Vlierberghe
, Jörg Trojan
, Frank T Kolligs
, Alan Weiss
, Steven Miles
, Antonio Gasbarrini
, Monica Lencioni
, Luca Cicalese
, Morris Sherman
, Cesare Gridelli
, Peter Buggisch
, Guido Gerken
, Roland M Schmid
, Corrado Boni

Nicola Personeni, Ziad Hassoun, Giovanni Abbadessa, Brian Schwartz, Reinhard Von Roemeling, Maria E Lamar, Yinpu Chen, Camillo Porta

Risultato della ricerca: Contributo in rivista › Articolo

436 Citazioni (Scopus)

Abstract

Tivantinib (ARQ 197), a selective oral inhibitor of MET, has shown promising antitumour activity in hepatocellular carcinoma as monotherapy and in combination with sorafenib. We aimed to assess efficacy and safety of tivantinib for second-line treatment of advanced hepatocellular carcinoma.

Lingua originale	Inglese
pagine (da-a)	55-63
Numero di pagine	9
Rivista	The Lancet Oncology
Volume	14
DOI	https://doi.org/10.1016/S1470-2045(12)70490-4
Stato di pubblicazione	Pubblicato - 2013

Keywords

Adult
Aged
Aged, 80 and over
Carcinoma, Hepatocellular
Disease-Free Survival
Double-Blind Method
Drug-Related Side Effects and Adverse Reactions
Female
Gene Expression
Humans
Kaplan-Meier Estimate
Liver Neoplasms
Male
Middle Aged
Neoplasm Staging
Protein Kinase Inhibitors
Proto-Oncogene Proteins c-met
Pyrrolidinones
Quinolines

Accesso al documento

10.1016/S1470-2045(12)70490-4

Altri file e collegamenti

Link a IRIS PubliCatt

Cita questo

Santoro, A., Rimassa, L., Borbath, I., Daniele, B., Salvagni, S., Van Laethem, J. L., Van Vlierberghe, H., Trojan, J., Kolligs, F. T., Weiss, A., Miles, S., Gasbarrini, A., Lencioni, M., Cicalese, L., Sherman, M., Gridelli, C., Buggisch, P., Gerken, G., Schmid, R. M., ... Porta, C. (2013). Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. The Lancet Oncology, 14, 55-63. https://doi.org/10.1016/S1470-2045(12)70490-4

@article{a38c5e1956f34089a4853d40e6cd1477,

title = "Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study",

abstract = "Tivantinib (ARQ 197), a selective oral inhibitor of MET, has shown promising antitumour activity in hepatocellular carcinoma as monotherapy and in combination with sorafenib. We aimed to assess efficacy and safety of tivantinib for second-line treatment of advanced hepatocellular carcinoma.",

keywords = "Adult, Aged, Aged, 80 and over, Carcinoma, Hepatocellular, Disease-Free Survival, Double-Blind Method, Drug-Related Side Effects and Adverse Reactions, Female, Gene Expression, Humans, Kaplan-Meier Estimate, Liver Neoplasms, Male, Middle Aged, Neoplasm Staging, Protein Kinase Inhibitors, Proto-Oncogene Proteins c-met, Pyrrolidinones, Quinolines, Adult, Aged, Aged, 80 and over, Carcinoma, Hepatocellular, Disease-Free Survival, Double-Blind Method, Drug-Related Side Effects and Adverse Reactions, Female, Gene Expression, Humans, Kaplan-Meier Estimate, Liver Neoplasms, Male, Middle Aged, Neoplasm Staging, Protein Kinase Inhibitors, Proto-Oncogene Proteins c-met, Pyrrolidinones, Quinolines",

author = "Armando Santoro and Lorenza Rimassa and Ivan Borbath and Bruno Daniele and Stefania Salvagni and \{Van Laethem\}, \{Jean Luc\} and \{Van Vlierberghe\}, Hans and J{\"o}rg Trojan and Kolligs, \{Frank T\} and Alan Weiss and Steven Miles and Antonio Gasbarrini and Monica Lencioni and Luca Cicalese and Morris Sherman and Cesare Gridelli and Peter Buggisch and Guido Gerken and Schmid, \{Roland M\} and Corrado Boni and Nicola Personeni and Ziad Hassoun and Giovanni Abbadessa and Brian Schwartz and \{Von Roemeling\}, Reinhard and Lamar, \{Maria E\} and Yinpu Chen and Camillo Porta",

year = "2013",

doi = "10.1016/S1470-2045(12)70490-4",

language = "English",

volume = "14",

pages = "55--63",

journal = "The Lancet Oncology",

issn = "1470-2045",

publisher = "Elsevier Limited",

}

Santoro, A, Rimassa, L, Borbath, I, Daniele, B, Salvagni, S, Van Laethem, JL, Van Vlierberghe, H, Trojan, J, Kolligs, FT, Weiss, A, Miles, S, Gasbarrini, A, Lencioni, M, Cicalese, L, Sherman, M, Gridelli, C, Buggisch, P, Gerken, G, Schmid, RM, Boni, C, Personeni, N, Hassoun, Z, Abbadessa, G, Schwartz, B, Von Roemeling, R, Lamar, ME, Chen, Y & Porta, C 2013, 'Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study', The Lancet Oncology, vol. 14, pagg. 55-63. https://doi.org/10.1016/S1470-2045(12)70490-4

TY - JOUR

T1 - Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study

AU - Santoro, Armando

AU - Rimassa, Lorenza

AU - Borbath, Ivan

AU - Daniele, Bruno

AU - Salvagni, Stefania

AU - Van Laethem, Jean Luc

AU - Van Vlierberghe, Hans

AU - Trojan, Jörg

AU - Kolligs, Frank T

AU - Weiss, Alan

AU - Miles, Steven

AU - Gasbarrini, Antonio

AU - Lencioni, Monica

AU - Cicalese, Luca

AU - Sherman, Morris

AU - Gridelli, Cesare

AU - Buggisch, Peter

AU - Gerken, Guido

AU - Schmid, Roland M

AU - Boni, Corrado

AU - Personeni, Nicola

AU - Hassoun, Ziad

AU - Abbadessa, Giovanni

AU - Schwartz, Brian

AU - Von Roemeling, Reinhard

AU - Lamar, Maria E

AU - Chen, Yinpu

AU - Porta, Camillo

PY - 2013

Y1 - 2013

N2 - Tivantinib (ARQ 197), a selective oral inhibitor of MET, has shown promising antitumour activity in hepatocellular carcinoma as monotherapy and in combination with sorafenib. We aimed to assess efficacy and safety of tivantinib for second-line treatment of advanced hepatocellular carcinoma.

AB - Tivantinib (ARQ 197), a selective oral inhibitor of MET, has shown promising antitumour activity in hepatocellular carcinoma as monotherapy and in combination with sorafenib. We aimed to assess efficacy and safety of tivantinib for second-line treatment of advanced hepatocellular carcinoma.

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Carcinoma, Hepatocellular

KW - Disease-Free Survival

KW - Double-Blind Method

KW - Drug-Related Side Effects and Adverse Reactions

KW - Female

KW - Gene Expression

KW - Humans

KW - Kaplan-Meier Estimate

KW - Liver Neoplasms

KW - Male

KW - Middle Aged

KW - Neoplasm Staging

KW - Protein Kinase Inhibitors

KW - Proto-Oncogene Proteins c-met

KW - Pyrrolidinones

KW - Quinolines

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Carcinoma, Hepatocellular

KW - Disease-Free Survival

KW - Double-Blind Method

KW - Drug-Related Side Effects and Adverse Reactions

KW - Female

KW - Gene Expression

KW - Humans

KW - Kaplan-Meier Estimate

KW - Liver Neoplasms

KW - Male

KW - Middle Aged

KW - Neoplasm Staging

KW - Protein Kinase Inhibitors

KW - Proto-Oncogene Proteins c-met

KW - Pyrrolidinones

KW - Quinolines

UR - http://hdl.handle.net/10807/52153

U2 - 10.1016/S1470-2045(12)70490-4

DO - 10.1016/S1470-2045(12)70490-4

M3 - Article

SN - 1470-2045

VL - 14

SP - 55

EP - 63

JO - The Lancet Oncology

JF - The Lancet Oncology

ER -

Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study

Abstract

Keywords

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo